Xuan Ying Poh

Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial

L. Rénia, L. Ng, E. Ren, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Selective transduction of astrocytic and neuronal CNS subpopulations by lentiviral vectors pseudotyped with Chikungunya virus envelope.

N. Mazarakis, A. Sgourou, I. Eleftheriadou, 2017, Biomaterials.

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

L. Rénia, L. Ng, R. Lin, 2022, Trials.

Neutrophil-Mediated Immunopathology and Matrix Metalloproteinases in Central Nervous System – Tuberculosis

J. Friedland, Fei-Kean Loh, C. W. Ong, 2022, Frontiers in Immunology.

Nos2−/− mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis

Q. H. Miow, Yu Wang, C. W. Ong, 2021, Journal of Neuroinflammation.

Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters

M. Tay, L. Rénia, P. MacAry, 2022, Journal of medical virology.

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant

S. Maurer-Stroh, R. Lee, M. Tay, 2023, The Lancet Regional Health - Western Pacific.